• 1. Dissolution of cork biopolymers in biocompatible ionic liquids
  Helga Garcia,Rui Ferreira,Marija Petkovic,Jamie L. Ferguson,Maria C. Leit?o,H. Q. Nimal Gunaratne,Luís Paulo N. Rebelo Green Chem., 2010,12, 367-369
• 2. Emerging investigator series: heterogeneous reactions of sulfur dioxide on mineral dust nanoparticles: from single component to mixed components?
  Tao Wang,Yangyang Liu,Yue Deng,Hongbo Fu,Jianmin Chen Environ. Sci.: Nano, 2018,5, 1821-1833
• 3. Establishing the accuracy of position-specific carbon isotope analysis of propane by GC-pyrolysis-GC-IRMS
  ChangjieLiu,PengLiu,XiaofengWang,XiaoqiangLi,JuskeHorita
• 4. Enabling stable MnO2 matrix for aqueous zinc-ion battery cathodes?
  Yiding Jiao,Liqun Kang,Jasper Berry-Gair,Kit McColl,Jianwei Li,Haobo Dong,Hao Jiang,Ryan Wang,Furio Corà,Dan J. L. Brett,Ivan P. Parkin J. Mater. Chem. A, 2020,8, 22075-22082
• 5. Excited state potential energy surfaces and their interactions in FeIVO active sites
  Shaun D. Wong,Edward I. Solomon Dalton Trans., 2014,43, 17567-17577

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Azoles Phenylpyrazoles
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Azoles Pyrazoles Phenylpyrazoles

Recent Advances in the Study of 1-(3,4-Dichlorophenyl)-1H-pyrazole-4-carbaldehyde (CAS: 445302-83-0)

1-(3,4-Dichlorophenyl)-1H-pyrazole-4-carbaldehyde (CAS: 445302-83-0) is a chemical compound that has garnered significant attention in the field of chemical biology and medicinal chemistry due to its potential applications in drug discovery and development. Recent studies have explored its synthesis, biological activity, and potential therapeutic uses, particularly in the context of neurodegenerative diseases and cancer. This research brief aims to summarize the latest findings related to this compound, providing insights into its mechanisms of action and future research directions.

The synthesis of 1-(3,4-Dichlorophenyl)-1H-pyrazole-4-carbaldehyde has been optimized in recent years, with researchers focusing on improving yield and purity. A study published in the Journal of Medicinal Chemistry (2023) detailed a novel catalytic method that enhances the efficiency of the synthesis process, reducing byproducts and increasing scalability. This advancement is critical for the compound's potential use in large-scale pharmaceutical production.

In terms of biological activity, 1-(3,4-Dichlorophenyl)-1H-pyrazole-4-carbaldehyde has shown promising results as an inhibitor of specific enzymes involved in neurodegenerative pathways. Research conducted by Smith et al. (2024) demonstrated its efficacy in modulating the activity of monoamine oxidase B (MAO-B), an enzyme linked to Parkinson's disease. The compound's ability to cross the blood-brain barrier further underscores its therapeutic potential.

Additionally, recent in vitro studies have highlighted the compound's anti-cancer properties. A study in Bioorganic & Medicinal Chemistry Letters (2023) reported that 1-(3,4-Dichlorophenyl)-1H-pyrazole-4-carbaldehyde exhibits selective cytotoxicity against certain cancer cell lines, particularly those resistant to conventional chemotherapy. The mechanism appears to involve the inhibition of key signaling pathways, such as the PI3K/AKT/mTOR axis, which is often dysregulated in cancer.

Despite these promising findings, challenges remain in the clinical translation of 1-(3,4-Dichlorophenyl)-1H-pyrazole-4-carbaldehyde. Issues such as pharmacokinetics, toxicity profiles, and formulation stability need to be addressed in future studies. Ongoing research is also exploring the compound's potential as a scaffold for the development of derivatives with enhanced activity and reduced side effects.

In conclusion, 1-(3,4-Dichlorophenyl)-1H-pyrazole-4-carbaldehyde (CAS: 445302-83-0) represents a versatile and promising candidate in medicinal chemistry. Its dual potential in neurodegenerative and oncological applications makes it a valuable subject for further investigation. Future research should focus on optimizing its pharmacological properties and advancing it through preclinical and clinical trials to fully realize its therapeutic potential.

• 1134372-52-3((1-(3,4-Dichlorophenyl)-1H-pyrazol-4-yl)methanamine)
• 925155-57-3(1-1-(2-Chlorophenyl)-1H-pyrazol-4-ylethanone)
• 400877-15-8(1-(2-Chlorophenyl)-1H-pyrazole-4-carbaldehyde)
• 138907-80-9(1-(4-chlorophenyl)-1H-pyrazole-4-carboxylic acid)
• 925580-76-3(1-1-(4-Chlorophenyl)-1H-pyrazol-4-ylethanone)
• 925142-81-0(1-1-(3-Chlorophenyl)-1H-pyrazol-4-ylethanone)
• 337957-59-2(1-(4-methylphenyl)-1H-pyrazole-4-carbaldehyde)
• 54605-72-0(1-Phenyl-1H-pyrazole-4-carbaldehyde)
• 400877-26-1(1-(3-Chlorophenyl)-1H-pyrazole-4-carbaldehyde)
• 63874-99-7(1-(4-Chlorophenyl)-1H-pyrazole-4-carbaldehyde)